Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on October 3, 2024. The filing addresses Item 8.01 (Other Events) and provides updates on the clinical development progress of the Company's product candidate, Haduvio, specifically regarding trials for chronic cough and idiopathic pulmonary fibrosis.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a clinical-stage biopharmaceutical company, this report focuses on operational milestones rather than financial performance data.
Material Changes and Clinical Updates
- Phase 2b CORAL Trial: The trial for chronic cough in patients with idiopathic pulmonary fibrosis has enrolled 50% of the targeted study enrollment required for the pre-specified sample size re-estimation (SSRE). The SSRE will be conducted after the last of these patients complete six weeks of treatment, with results expected in December 2024. Potential outcomes include maintaining the current sample size (N=160), upsizing within a pre-specified range, or evaluating for futility. Assuming no sample size adjustments, topline results are expected in the first half of 2025.
- Human Abuse Potential Study: Dosing for this study has been completed. Topline results are expected in December 2024.
- Phase 2a RIVER Trial: The trial for refractory chronic cough has enrolled the planned sample size but remains open to allow for additional enrollment to approximate stratification targets. Topline results are now expected in the first quarter of 2025.
Guidance, Outlook, and Risks
Management provided forward-looking statements regarding the timing of clinical trial results and the potential outcomes of the SSRE. The Company highlighted significant risks, including uncertainties regarding the success and timing of product development, the predictive nature of early clinical data, regulatory authority views, and the ability to fund future operations and clinical trials. The filing explicitly states that actual results may differ materially from expectations.
Key Facts for Investor Verification
- Verify the specific date and outcome of the Sample Size Re-estimation (SSRE) for the CORAL trial expected in December 2024.
- Monitor the topline results of the Human Abuse Potential study and the RIVER trial scheduled for late 2024 and early 2025, respectively.
- Review the Company's most recent Form 10-Q (for the quarter ended June 30, 2024) to assess current cash runway and liquidity, as this 8-K does not contain financial figures.
- Confirm whether the CORAL trial sample size is adjusted following the SSRE, as this will impact the timeline for topline results.